Among the primary causes for attrition in early clinical development are safety and pharmacology issues. In the case of biopharmaceuticals, immunogenic and hypersensitivity reactions are perhaps the largest contributors to such early clinical failures
This 30-minute webinar demonstrates how metabolomics can be a powerful tool in dermatological and skincare research.
This 30-minute webinar will introduce a robust, highly sensitive biomarker development program that leverages a revolutionary metabolomics discovery platform to improve the range of analytes that can be measured routinely and reliably.
This 30-minute webinar provides a brief overview of recent advances in metabolomics technology and methodology, which together have advanced the field of metabolomics.
Adaptive trial design is critical in all phases of oncology drug development and helps overcome many hurdles of traditional study design. In a recent webinar, PPD’s Dirk Reitsma, M.D., vice president, global product development, and Niklas Morton, vice president, global biostatistics, programming and medical writing, analyzed the incorporation of adaptive trial design in oncology trials. They were joined by Scott Berry, Ph.D., president and senior statistical scientist with Berry Consultants, to assess the early decision making benefits that are critical to the decreasing drug development time and providing increased benefit to patients.
Predicting potential problems serves no purpose if it is not accompanied by adequate corrective actions or mitigation strategies to address them. This webinar will also discuss risk mitigation options for both early and late stage development programs.
Dr. Noel Smith will describe Lonza’s Epibase™ in silico and in vitro tools for acceleration of the design and assessment of effective subunit vaccines.
|
|
|
|
|
|
|
|
|